Medication Management

Pre-Treatment Considerations

The American College of Cardiology recommends ensuring normal potassium and magnesium levels before initiating therapy, and considering periodic electrolyte monitoring, particularly if the patient is on diuretics or has gastrointestinal illness 1
The American College of Cardiology advises avoiding concurrent use of other QT-prolonging medications 1
Citalopram may cause QT prolongation associated with Torsade de Pointes, ventricular tachycardia, and sudden death at daily doses exceeding 40 mg/d, particularly in patients with risk factors such as age > 60 years, congenital long QT syndrome, and concomitant use of other QT-prolonging medications, as noted by the American Academy of Child and Adolescent Psychiatry 2

Patients with risk factors such as age > 60 years, congenital long QT syndrome, bradycardia, hypokalemia or hypomagnesemia, recent acute myocardial infarction, uncompensated heart failure, and concomitant use of other QT-prolonging medications are more vulnerable to citalopram-induced QT prolongation 2

The following risk factors increase the risk of QT prolongation:

Risk Factor	Description
Bradycardia	Heart rate <60 bpm
Female gender	Increased risk of torsades de pointes
Recent conversion from atrial fibrillation	Increased risk of torsades de pointes
Congestive heart failure	Increased risk of torsades de pointes
Electrolyte abnormalities	Hypokalemia, hypomagnesemia
Concomitant use of multiple QT-prolonging drugs	Increased risk of torsades de pointes
Genetic predisposition to QT prolongation	Increased risk of torsades de pointes
Age > 65 years	Increased risk of torsades de pointes

3, 4, 5

The FDA has established maximum dosing limits for citalopram, including 40 mg/day for most adults, 20 mg/day for patients >60 years, 20 mg/day for CYP2C19 poor metabolizers, and 20 mg/day for patients with hepatic impairment, and recommends baseline ECG before starting treatment and follow-up ECG monitoring, particularly when using maximum recommended doses or in patients with risk factors 2
Normal QTc values are considered to be <430 ms in males and <450 ms in females, according to the American College of Cardiology 6
The American Heart Association recommends monitoring ECG at least every 8-12 hours during treatment with medications that may prolong the QT interval in patients with risk factors 7
Baseline ECG before starting medications that may prolong the QT interval and repeat ECG at 7 days after initiation of therapy and following any dosing changes are recommended by the American College of Cardiology 6

Considering dose reduction or discontinuation if QTc increases by >60 ms from baseline, QTc reaches >500 ms, or the patient develops QT-related arrhythmias (T wave alternans, polymorphic PVCs) is recommended by the American College of Cardiology 8, 9
The American Heart Association recommends discontinuing medications that prolong the QT interval immediately if QT prolongation occurs during administration, continuing ECG monitoring until the QTc decreases, and correcting electrolyte abnormalities (especially potassium and magnesium) 10
The American College of Cardiology suggests removing other QT-prolonging medications if possible and administering 2g of IV magnesium regardless of serum magnesium level if torsades de pointes occurs 6
The European Society of Cardiology recommends identifying and removing QT-prolonging medications as the first critical step in managing QT prolongation, with a Class I recommendation and Level of Evidence A 3

Regular EKG monitoring is recommended for patients at high risk of QT prolongation, with checks every 2 weeks after starting medications that may prolong the QT interval and then monthly, as well as after adding any other QT-prolonging medications, according to the European Respiratory Journal 11
Electrolyte levels should be regularly checked and corrected if necessary, with particular attention to maintaining potassium levels between 4.5-5 mEq/L, although specific targets may vary based on individual patient needs and guidelines from relevant medical societies 11
Educating patients to report symptoms like palpitations, lightheadedness, or syncope is recommended by the American Heart Association 9
When prescribing citalopram, it is recommended to assess cardiac risk factors before initiating therapy, consider baseline ECG, especially in high-risk patients, start with lower doses in elderly patients and those with risk factors, avoid combining with other QT-prolonging medications, and monitor for symptoms of cardiac arrhythmias 2
The American Heart Association suggests considering alternative medications that have less effect on the QT interval, such as metoclopramide, prochlorperazine, haloperidol (in low doses), dexamethasone, and benzodiazepines, when medications that prolong the QT interval are contraindicated due to QT prolongation 10